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Clostridium difficile infection (CDI) is a global health threat associated with high rates
of morbidity and mortality. Conventional antibiotic CDI therapy can result in treatment
failure and recurrent infection. C. difficile produces biofilms which contribute to its
virulence and impair antimicrobial activity. Some bacteriophages (phages) can penetrate
biofilms and thus could be developed to either replace or supplement antibiotics. Here,
we determined the impact of a previously optimized 4-phage cocktail on C. difficile
ribotype 014/020 biofilms, and additionally as adjunct to vancomycin treatment in
Galleria mellonella larva CDI model. The phages were applied before or after biofilm
establishment in vitro, and the impact was analyzed according to turbidity, viability
counts and topography as observed using scanning electron and confocal microscopy.
The infectivity profiles and efficacies of orally administered phages and/or vancomycin
were ascertained by monitoring colonization levels and larval survival rates. Phages
prevented biofilm formation, and penetrated established biofilms. A single phage
application reduced colonization causing extended longevity in the remedial treatment
and prevented disease in the prophylaxis group. Multiple phage doses significantly
improved the larval remedial regimen, and this treatment is comparable to vancomycin
and the combined treatments. Taken together, our data suggest that the phages
significantly reduce C. difficile biofilms, and prevent colonization in the G. mellonella
model when used alone or in combination with vancomycin. The phages appear to be
highly promising therapeutics in the targeted eradication of CDI and the use of these
models has revealed that prophylactic use could be a propitious therapeutic option.
Keywords: Clostridium difficile, Clostridium difficile infection, biofilms, Galleria mellonella, bacteriophages,
bacteriophage therapy
INTRODUCTION
Clostridium difficile is an important human and animal pathogen and a major cause of
pseudomembranous colitis where it accounts for 15–39% of antibiotic-stimulated toxin-mediated
diarrhea (McFarland, 2009; Viswanathan et al., 2010). C. difficile infections (CDI) are becoming
increasingly severe due to limited treatment options and the emergence of pathogenic ribotypes
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(Freeman et al., 2010; Zucca et al., 2013). Complications of
the disease can also arise from antibiotic resistance, leading
to relapse, increased health care-associated costs and death in
10% cases (Wiegand et al., 2012; Lessa et al., 2015; Vindigni
and Surawicz, 2015). Therefore, there is a need for specific and
efficient strategies for the targeted eradication of this pathogen.
The pathogenicity of C. difficile is linked to potent cytotoxins
(toxin A, B and binary toxin AB) which together are
responsible for the damage of the epithelial lining leading to
pseudomembranous colitis (Lyerly et al., 1988; Carter et al., 2007;
Lyras et al., 2009). Other factors such as fimbriae and surface
layer proteins contribute to its motility and adhesion to the
ileum and caecum where the disease is most prominent (Borriello
et al., 1988; Tasteyre et al., 2000). In addition, their hardy spores
resist heat and desiccation, thus playing a significant role in
their spread, survival and disease (Akerlund et al., 2008; Burns
et al., 2011). Of particular relevance to this paper, C. difficile
also produces biofilms, which consist of aggregates of cells
embedded in self-produced extracellular polymetric substance
(EPS) (Branda et al., 2005; Dawson et al., 2012; Ðapa et al.,
2013). The EPS matrix binds the spores and vegetative cells,
and provides protection for the bacteria against oxygen stress
and enhances their adhesion to abiotic surfaces (Dawson et al.,
2012). Therefore, biofilms contribute to C. difficile virulence
by potentially enhancing persistence and proliferation of the
pathogen in the environment, and during active infection where
they could interfere with the activity of antimicrobial agents and
treatment of the disease.
The conventional CDI treatment relies solely on three
antibiotics: metronidazole, vancomycin and fidaximicin,
although limitations to their use have been reported (Aslam
et al., 2005; Pepin, 2008; Crawford et al., 2012). Metronidazole
is not effective for the treatment of all ribotypes, vancomycin
is predominantly used as a treatment of last resort due to the
possibility of resistance emergence. Fidaximicin is much newer
and is not cost effective as a first-line treatment for some strain-
specific CDIs (Wiegand et al., 2012; Bartsch et al., 2013; Chilton
et al., 2014). In terms of mechanisms of action, metronidazole
disrupts DNA replication, vancomycin targets the bacterial
cell wall and fidaximicin hinders RNA polymerase activity
(Watanakunakorn, 1984; Löfmark et al., 2010; Venugopal and
Johnson, 2012). Clearly antibiotic action is hampered by the
limited access to the C. difficile due to obstacles posed by the
hardy spores and biofilm formation. Pertinent to the biofilm is
the EPS matrix which could be overcome by antimicrobial agents
such as bacteriophages (phages) (Parasion et al., 2014; Chan and
Abedon, 2015; Abedon, 2016).
Phages are viruses that specifically infect bacteria. By infecting
and then lysing biofilm-causing bacteria they have been shown
to prevent biofilm formation (Parasion et al., 2014; Chan and
Abedon, 2015; Dalmasso et al., 2015; Abedon, 2016). In addition,
the EPS-depolymerases carried by some phages, which have a
different function than lysins (lysis of the bacterial cell), impact
biofilms by degrading EPS matrix (Parasion et al., 2014; Chan
and Abedon, 2015). This enzyme activity presumably exposes the
bacterial cells to antimicrobial agents, and provides access for
phages to the receptors found on the cell wall, leading to infection
and lysis. These advantages of phages over antibiotics is attractive
and could be exploited either for phage mediated eradication of
C. difficile, or to enhance antibiotic activity.
Phages have been developed for therapeutic purposes to
treat bacterial infections caused by Staphylococcus, Streptococcus,
Pseudomonas, Proteus, and Escherichia coli (Slopek et al., 1987;
Abedon et al., 2011; Brüssow, 2012). In addition to medical
uses, their safety, specificity and ability to replicate in situ has
meant that phages both can and are currently used in the food
industry as alternatives to antibiotics and as decontamination
agents (EBI Food Safety, 2007; Hagens and Loessner, 2010;
Kumari et al., 2011). Although several C. difficile phages have
been characterized, few studies have focused on their potential
applications for the treatment of CDI (Zucca et al., 2013;
Hargreaves and Clokie, 2014; Nale et al., 2016). Most therapeutic
studies have investigated single phages, and reported the isolation
of resistant and lysogenic clones (Ramesh et al., 1999; Govind
et al., 2009; Meader et al., 2010, 2013; Nale et al., 2016).
In contrast, our previous work demonstrated that the use of
optimized phage combinations could mitigate lysogeny and
resistance in vitro, and could reduce colonization and extend the
life expectancy of animals in a hamster model of CDI (Nale et al.,
2016).
The other previous work on therapeutic CDI phages has
concentrated on exploiting an artificial human gut model
(Meader et al., 2010, 2013), and on the hamster model (Ramesh
et al., 1999; Govind et al., 2011; Nale et al., 2016). Both are
useful but have limitations. The artificial human gut model
has been used to reveal many facets of enteric pathogens but
is has a large footprint and the experiments are technically
difficult to run. Although the hamster CDI model is good due
to the ability of the animals to demonstrate various clinical
symptoms of the disease that are comparable to humans,
these animals are susceptible to the toxins, and succumb to
the disease easily (Price et al., 1979; Best et al., 2012). The
technical limitations of these models, the lengthy process for
ethical/licenses approvals, and limitations associated with cost
and space are causing researchers to shift interest toward
exploring other substitutes for C. difficile research. Recent
studies, for example, have examined zebra fish embryos to test
C. difficile toxin B clones (Hamm et al., 2006; Lanis et al.,
2010).
Galleria mellonella larvae have been reported to be a suitable
alternative model to larger mammals for bacterial colonization
studies (Ramarao et al., 2012) and an excellent tool for
pharmacokinetics studies of antimicrobials (Hill et al., 2014). The
model has also been used to study pathogenesis of bacteria such as
Pseudomonas aeruginosa, Listeria monocytogenes, Bacillus cereus,
and Francisella tularensis (Miyata et al., 2003; Aperis et al., 2007;
Fedhila et al., 2010; Mukherjee et al., 2010) and phage therapy for
Burkholderia cepacia and P. aeruginosa (Seed and Dennis, 2009;
Beeton et al., 2015). However, no studies have been published
to date to examine how useful Galleria would be as a model for
CDI colonization, or subsequent phage therapeutic studies. There
have been limited studies on the optimal dosing of phages and it is
likely that significant amounts of knowledge can be gained from
this model to inform subsequent animal experiments.
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In this study, we examined the ability of C. difficile phages to
target this bacterium in two models of infection. We investigate
the efficacy of an optimized phage cocktail to prevent or treat
C. difficile biofilms, and as a stand-alone treatment or combined
with vancomycin in the G. mellonella larvae CDI model. We show
that the phages prevent biofilm formation in vitro, and penetrate
into and reduce established biofilms. In the Galleria model, the
phages are most effective when used prophylactically, and in the
presence of vancomycin, with multiple doses required to produce
comparable results in the remedial regimen. It is clear that phages
are able to impact C. difficile biofilms and significantly reduce
the extent of colonization in a G. mellonella model of CDI and
therefore appear to have great potential for the treatment of this
bacterial pathogen. These models can be used to pursue aspects
of phage therapy development in the future, such as to develop
dosing and timing regimens.
MATERIALS AND METHODS
In vitro Phage Treatment of Biofilms
Bacterial Isolates and Phages
Six C. difficile ribotype 014/020 human clinical strains
(CD105LC2, ATJ, AIP, ATK, TL176 and AUS1022) were
examined in this study (Nale et al., 2016). The biofilm
characteristics of R20291 were previously established and
therefore was used as a control strain in the biofilm preliminary
assays (Dawson et al., 2012; Ðapa et al., 2013). The four phages
examined, CDHM1, 2, 5, and 6 were previously isolated from our
laboratory and propagated individually on the environmental
C. difficile strain, CD105HE1 (Hargreaves et al., 2014; Nale
et al., 2016). The filtered phage lysates (using 0.22 µl filters,
Merck Millipore Ltd, Cork, Ireland) were mixed equally to form
the cocktail. All the bacterial strains and phages tested were
preserved in 25% glycerol stocks at−80◦C.
Establishment of Biofilm Characteristics of the
Bacterial Strains
Prior to phage treatment, the biofilm characteristics of the test
strain CD105LC2 was first established in vitro on 12-well plates
(Greiner Bio-One Ltd, UK) and the feature compared with the
other five ribotype 014/020 strains using methods previously
described (Ðapa et al., 2013). Briefly, 48 h C. difficile cultures
were produced on brain heart infusion (BHI) (Oxoid, UK)
agar plates supplemented with 7% defibrinated horse blood
(TCS Biosciences Ltd, UK). Broth cultures were prepared by
inoculating a bacterial colony into 5 ml brain heart infusion
supplemented (BHIS) with 0.1% w/v each of Ly-cysteine (Sigma–
Aldrich, UK) and 5 mg/ml yeast extract (Oxoid, UK) and
incubated at 37◦C anaerobically for 18–24 h. Afterward, 1:10
dilutions of the overnight cultures (107 CFU/ml) were prepared
in pre-reduced BHIS broth and 3 ml aliquots were added to
the 12-well plates and incubated for 1–5 days. After each day
the planktonic and biofilm vegetative cells and heat-resistant
(at 65◦C for 3 h) spores were enumerated on BHI agar and
Brazier’s cefoxitin, cycloserine and egg yolk (CCEY) agar plates
(BioConnections, UK) respectively. To determine the biofilm
mass, planktonic cultures from the wells were carefully removed
to expose the thin biofilm layer at the bottom. The wells
were washed twice with sterile phosphate buffered saline (PBS)
and stained with 2 ml 0.1% filtered crystal violet followed by
incubation at room temperature for 1 h. After washing off the
crystal violet three times with PBS, 1 ml of absolute methanol was
applied and incubated at room temperature for 5 min to extract
the biofilm-bound stain. Approximately 250 µl was transferred
to a 96-well plate and absorbance was read at 595 nm (Dawson
et al., 2012; Ðapa et al., 2013).
Phage Treatment of Biofilms
Having established the biofilm characteristics of the test strain,
CD105LC2, a fresh biofilm of this strain was produced from a
dilution of the overnight culture (Set 1) and subjected to four
different phage treatment regimens (Sets 2–5, Table 1) using
300 µl of the single or phage combination (at 109 PFU/ml,
MOI = 10). Sets 2, 3, and 4 represent biofilm pre-treatment
regimens where phages were added: 1 h prior to bacterial
exposure (Set 2), 1 h post-bacterial inoculation (Set 3) or
simultaneously with the bacteria (Set 4). The only post- treatment
regimen was Set 5. In this treatment, maximum biofilms (at
24 h) were established first and planktonic cultures removed as
described above before treating them with the phages as shown
in Table 1. The treated biofilms were further incubated for 24 h.
After each treatment, the resultant vegetative cells and spores
TABLE 1 | Experimental set-up for the pre- and post-biofilm regimens with single and combined phages.
Regimen Biofilm phage treatment regimens Treatment
Set 1 Control (Untreated biofilms) 3 ml of 10% dilution of ON bacterial culture in pre-reduced BHIS was added to the wells.
Set 2 Pre-treatment 1 3 ml of the 10% diluted culture was added to the wells and incubated for 1 h. Afterward, 300 µl phage
lysate/cocktail was added.
Set 3 Pre-treatment 2 300 µl of phage lysate/cocktail was added to the wells and incubated for 1 h. After incubation, 3 ml of
10 % diluted culture was added.
Set 4 Pre-treatment 3 3 ml of 10% diluted bacterial culture was mixed with 300 µl of phages and added to the wells.
Set 5 Post-treatment 3 ml of 10 % diluted bacterial culture was added to the plates and incubated overnight. Afterward, the
planktonic cells were washed out and 300 µl of phage lysate/cocktail was added.
Phages were propagated individually (109PFU) and mixed together in equal proportions to constitute the cocktail. Biofilm treatment was conducted with 300 µl of the
phage cocktail and 3 ml of the 10% diluted overnight bacterial cultures (MOI = 10) or on established biofilms of a C. difficile 014/020 isolate (CD105LC2). All treated
biofilms were further incubated for 24 h before enumeration of the vegetative cells and spores.
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were enumerated and the biofilm mass determined as described
above.
Phage Treatment of Colony Biofilms
To determine the effect of phage treatment on the topology
of biofilms, colony biofilms were produced on membrane filter
disks (Merck Millipore Ltd, Ireland) and treated with the phage
cocktail. To do this, the filter disks were sterilized both sides using
Stratalinker UV crosslinker 2400 (Strategene, US) at 9999 µm
setting. The sterilized disks were aseptically transferred onto BHI
agar plates and 5µl of a 10-fold dilution of the overnight bacterial
culture was applied onto the filter disks. After 24 h incubation, a
set of membrane disks for each day was transferred onto a fresh
BHI agar plate and this was repeated up to 5 days. For phage
treatments, 50µl of the phage cocktail was gently applied to cover
the entire surface of the biofilm after transferring biofilms to fresh
medium each day. The treated biofilms were further incubated
for an additional 24 h. Biofilms for each day (phage-treated and
control) were removed and transferred to a tube containing 1 ml
of cold BHI and vortexed (3000 rpm/min for 30 s) to dislodge the
biofilm from the membranes. The membranes were removed and
the resultant cultures were washed three times in ice-cold BHI
and centrifuging at 15 000 g for 5. The vegetative cells and spores
were enumerated using methods described above.
Scanning Electron and Confocal Microscopy
To conduct scanning electron microscopy (SEM) analysis on
the biofilms, a set of phage-treated and control biofilms on
the membrane disks were transferred to 12-well plates and
sterilized with 1 ml of 2.5% gluteraldehyde (v/v in PBS)
for at least 24 h. The membranes were processed through
several washes in distilled, de-ionized water, followed by 30-min
dehydration steps through a 30, 50, 70, 90, and 100% ethanol
series. After two more 20-min washes through 100% analytical
grade ethanol, the membranes were gradually infiltrated with
Hexamethyldisilazane (HMDS) by 1 h washes in 2:1, 1:1 and
finally 1:2 mixtures of ethanol:HMDS, followed by two 30-
min washes in 100% HMDS. The HMDS was removed, and
membranes were air dried overnight. Dried membranes were
mounted onto 12.5 mm aluminum stubs and sputter coated with
gold/palladium using a Quorum Q150T ES coating unit. Samples
were observed, and the images recorded using Hitachi S3000H
scanning electron microscope with an accelerating voltage of
10 kV.
For the confocal analysis, a different set of phage-treated and
untreated colony biofilms were prepared on membrane filters
as described and stained using FilmTracer Live/Dead biofilm
Viability kit according to the manufacturer’s recommendations
(ThermoFisher Scientific, UK). Membranes were sterilized with
the glutaraldehyde for 24 h. Confocal fluorescence imaging was
conducted as previously described (Osman et al., 2016).
In vivo Analysis of Phage Therapy Using
the Galleria mellonella Model
Preparation of Bacterial Inoculum
A dilution of the overnight inoculum of the bacteria was
prepared as above and incubated until OD550 of 0.2 was attained.
The culture was then centrifuged at 15 000 g for 5 min and
the resultant pellet was re-suspended in cold BHI to a final
concentration of 1× 107 CFU/mL.
Bacterial Infection, Colonization and Treatment of
G. mellonella Using a Single Phage Dose
Larvae of G. mellonella were obtained from Live Food UK
Ltd. (Rooks Bridge, UK). On arrival, the larvae were stored
immediately at 4◦C and used within 1 week. Larvae with
approximate weight of 0.25–0.30 g were selected for in vivo
analysis (Abbasifar et al., 2014). The larvae were surface-sterilized
with cotton swaps dipped in 70% ethanol. A single dose (in
10 µl) of either 105 CFU of bacterial inoculum, 106 PFU of phage
cocktail or BHI broth was administered via the oral route using
a 10-µl Hamilton syringe pump. Four randomly selected larvae
were examined in each treatment regimen at 37◦C in plastic Petri
dishes. The insects remained unfed throughout the experiment
(Ramarao et al., 2012). Two control groups were observed: the
first received only bacteria (Control CD105LC2) and the second
a dose of the phage cocktail (Control Phage). The treatment
models were divided into either prophylactic or remedial
groups. In the prophylactic model, phages were administered
2 h before bacterial infection (Phages + CD105LC2) or given
simultaneously with the bacteria (Phages + CD105LC2 (s)). In
the remedial group, bacteria were administered 2 h before the
phage treatment (CD105LC2+ Phages).
Insects were considered dead when they become inert and
turned black in color (Ramarao et al., 2012). Experiments were
repeated three times. Survival curves were plotted using the
Kaplan-Meier method in GraphPad Prism 6, and differences in
survival rates were calculated by using the Log-rank (Mantel-
Cox) test.
Bacterial and Phage Recovery from the Larvae
At the end of the experiment, the larvae were dissected
dorsoventrally, the heamolymph extracted into ice-cold BHI, and
phage and bacteria enumerated as described above. C. difficile
colonies were confirmed with colony PCR targeting the C. difficile
16S rRNA (Rinttilä et al., 2004). For recovery of phages,
homogenized heamolymph mixtures were centrifuged at 5000 g
for 10 min at 4◦C and the filtered supernatants were assayed
for phages using spot test on the phage propagating host,
CD105HE1, as the indicator strain. Recovery of phages from the
feces was conducted by combining and suspending excreta from
all four larvae in a group into 1 ml of cold BHI and incubated
at 4◦C for 1 h. The centrifuged and filtered supernatants were
enumerated for phage presence as above. Data were analyzed
using GraphPad Prism 6. All in vivo experiments were performed
at least thrice.
G. mellonella DNA Extraction and qPCR
Heamolymph from the four larvae from the treatment groups
above were combined and DNA was extracted from them using
DNeasy Blood & Tissue Kit (Qiagen, Germany). Approximately,
50 ng of DNA from each group of larvae was subjected to RT-
PCR targeting the C. difficile 16S rRNA using 7500 Fast Real Time
PCR system with Fast SYBR Green Master mix (Thermo Fisher
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Scientific, USA). Data was compared with standard CFU/ml
counts in the growth curve of the test strain and analyzed using
GraphPad Prism 6.
Treatment of G. mellonella Using Multiple Phage
Doses
Since the above phage treatment was conducted using a single
dose of the phage cocktail, further experiments were conducted
to determine if multiple phage doses could improve the treatment
regimen. To do this, five groups of larvae were given a mixture of
phages/bacteria at the 0 h. This is the only treatment in group A,
but in group B larvae subsequently received an additional single
dose of phage cocktail at 6 h while group C received 2 doses at 6
and 12 h (Table 2). Group D larvae received three doses of phages
at 6, 12 and 24 h while group E received 4 doses at 6, 12, 24, and
48 h (Table 2). Survival rates were recorded every 12 h for 72 h.
Phage/Antibiotic Combined Treatment on the Larvae
After phage therapy was established on the larvae, the phages
were tested as adjunct to vancomycin, a commonly used
antibiotic for CDI. Prior to the combined treatment, the windows
of opportunity during which phages may be most effective
as prophylactic therapeutics was determined by administering
the phages to the larvae first. Time delays of 2 h (A, Phage
prophylactic 1), 4 h (B, Phage prophylactic 2), 6 h (C, Phage
prophylactic 3) or 12 h (D, Phage prophylactic 4) were observed
before exposing them to bacterial infection (Table 3). To
determine if the phage prophylaxis would aid vancomycin
treatment, insects were given phages and in 2 h intervals
challenged with bacteria and given vancomycin (64 µg/g,
MIC ≥ 1 µg/ml) (E, Phage prophylaxis 5). Similarly, the
ability of vancomycin prophylaxis to enhance phage therapy
was also tested in treatment F (vancomycin prophylaxis) where
vancomycin was given first and subsequently bacteria and
phages were given at 2 h intervals respectively (Desbois and
Coote, 2011). The treatments were compared with vancomycin
treatment, (G, vancomycin given 2 h after exposure to bacteria) or
vancomycin/phage pre-treatments, (H, vancomycin and phages
were given simultaneously before exposure to bacteria 2 h later)
TABLE 2 | Multiple phage dose regimens observed in the remedial
treatments on G. mellonella larvae model of CDI.
Time to phage dose (h) Phage dose regimens
Control A B C D E
0 B P, B P, B P, B P, B P, B
2 P P P P
6 P P P
24 P P
48 P
72 Cull Cull Cull Cull Cull Cull
Larvae were inoculated with a mixture of phages (P) (106PFU) and/or bacteria
(B) (105 CFU) in 10 µl volume and subsequently treated with additional doses of
phages at the indicated time points. At the end of the experiment larvae were killed
(culled) by placing them in −20◦C for 5 min.
or phage/vancomycin remedial regimen (I, vancomycin/phage
simultaneously given 2 h post bacterial challenge) (Table 3).
Because CDI takes advantage of dysbiosis in the gut, another
group of larvae were first treated with clindamycin (30 µg/g,
MIC ≥ 1.125 µg/ml) to suppress bacterial commensals in the
haemolymph. Subsequently, after 24 h the larvae were exposed
to either bacteria followed by a dose of phage cocktail (J,
Clindamycin pre-treatment 1) or given phage first before the
bacteria (K, Clindamycin pre-treatment 2). All treatment groups
were compared to the control bacterial group (L, which received
just bacteria) (Table 3).
Larvae were culled at the 60th hour except for groups J and K,
which required additional 12 h after the last exposure (Table 3).
RESULTS
C. difficile Strains Have Different Biofilm
Characteristics
To determine the characteristics of the test strain, CD105LC2,
prior to phage treatment, we first established its ability to
produce biofilms and compared this feature to other ribotype
014/020 strains and to the reference strain, R20291 (ribotype
027). In preliminary biofilm assays, absorbance readings showed
that maximum biofilm was produced at 24 h. Therefore, all
subsequent analyses were conducted on biofilms formed at this
time. The ribotype 014/020 strains produced different levels
of biofilm (Supplementary Figure S1A). ATJ, AIP, AUS1022
and TL176 were similar at OD595 ∼1.1, while the other two
strains, ATK and CD105LC2 had readings of ∼1. 5. The biofilm
produced by R20291 strain (OD595∼1.7) at 24 h is comparable to
previously published data (Dawson et al., 2012; Ðapa et al., 2013).
Analysis of viability counts also suggests that variable quantities
of spores/vegetative cells are produced by the ribotype 014/020
strains both in the biofilms as well as in the planktonic cultures
(Supplementary Figure S1B). Generally, there were higher spore
counts in the planktonic cultures (105–107 CFU/ml) than in the
biofilms (102–104 CFU/ml) but higher levels of vegetative cells
in the biofilms (106–108 CFU/ml) compared to the planktonic
cultures (102–104 CFU/ml) (Supplementary Figure S1B).
Phage Treatment Regimens on
C. difficile Biofilms
Having established the biofilm characteristics of the test strain,
we determined the impact of phages on biofilm formation. We
examined the activity of the individual and combined phages
when applied before or after the biofilm establishment, compared
to the untreated biofilm (Set 1, Figure 1A). In all of the
pre-treatment regimens examined (Sets 2–4), vegetative cells
were completely eliminated in the planktonic cultures when
treated with the phage combination (Figures 1B–E). When
bacterial growth was established for an hour before phage
treatment (Set 2), vegetative cells were eliminated but ∼10
and ∼ 102 CFU/ml of spores and vegetative cells, respectively,
were detected in the biofilms (Figure 1B). Interestingly, when
the phages were added first (Set 3), biofilm establishment was
prevented and no bacteria were detected either in the biofilm
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TABLE 3 | Phage prophylaxis regimens and phage/vancomycin combined treatment in G. mellonella larvae.
Time (h) → 0 2 4 6 12 24 25 60 72
Treatments↓
A, Phage prophylaxis 1 P B Cull
B, Phage prophylaxis 2 P B Cull
C, Phage prophylaxis 3 P B Cull
D, Phage prophylaxis 4 P B Cull
E, Phage prophylaxis 5 P B V Cull
F, Vancomycin prophylaxis 1 V B P Cull
G, Vancomycin treatment B V Cull
H, Vancomycin/phage prophylaxis VP B Cull
I, Vancomycin/phage remedial regimen B VP Cull
J, Clindamycin pre-treatment 1 C B P Cull
K, Clindamycin pre-treatment 2 C P B Cull
L, Control bacteria B Cull
The larvae were inoculated with 10 µl of phages (P), vancomycin (V) and/or clindamycin (C) at the indicated times. Bacterial enumeration from each larva was conducted
from inactivated (culled) larva.
or planktonic cultures (Figure 1C). When bacteria and phages
were added simultaneously (Set 4), ∼103 CFU/ml of spores were
recorded in the planktonic culture (Figure 1D). In the post-
biofilm regimen (Set 5), phages were less effective and ∼102
and 104 CFU/ml vegetative cells and spores were recovered
respectively (Figure 1E). In contrast to treatments with the phage
combination, the single phage treatments were less effective
(Figures 1B–E).
Bacterial Enumeration and Microscopy
Analysis Confirmed That Phages Can
Penetrate C. difficile Biofilms
To further investigate the effect of phages on the established
biofilms, we used scanning electron and confocal microscopy to
determine the physical changes in the properties of the colony
biofilms. The topology of the untreated days 1, 2, 3, and 4
biofilms have evenly distributed cells (Figure 2A). In contrast,
the surface of the phage-treated day 1 biofilms had distinct
lysed zones (plaques, represented by green arrows) of ∼180–
300 µm diameter distributed on the surface but intact bacterial
cells were observed around the edges of the lysed zones (orange
arrows) (Figures 2B,C). Under higher magnifications, it was clear
that phage lysis was selective for vegetative cells only, leaving
the spores (yellow arrows) and spore mother cells intact (blue
arrows) (Figure 2D). Examination of the lysed zone of day 2
biofilms (Figures 2E,F) revealed elongated cells measuring 15–
100 µm in length (indicated using a red arrow) and spores
(Figure 2F). These elongated cells were only present in the lysed
parts of the biofilm. Similar lysed zones were seen in the phage
treated biofilms after 3 and 4 days (Figures 2G,H respectively)
but more spores were seen in day 4 biofilm (Figure 2H). At
day 5, no plaques were observed but spores, spore mother cells
and disintegrated cells (indicated using a purple arrow) were
observed in the control and phage-treated biofilms (Figures 2I,J
respectively).
Phage treatment on the biofilm resulted in a ∼0.5–1 log
reduction in vegetative cells for 1–4 days old biofilms, but
a negligible effect on the day 5 biofilm cells was observed.
Spore formation also progressed daily despite phage treatment
(Figure 2K).
Analysis of live or dead bacteria in the biofilms using
differential staining and confocal microscopy confirmed the lysed
zones (green arrows) and the unaffected areas around the zones
(orange arrows) (Figure 3A). In addition, the elongated cells
observed in the lysed zones were dead cells as stained by the red
propidium iodide dye (Figures 3B–D).
Efficacy of Phage Prophylactic and
Remedial Regimens on G. mellonella
Larva
To further test the ability of the phages for prophylactic or
remedial treatment for CDI we determined their efficacy in the
G. mellonella larvae using the same bacterial strain and phage
combination used for the biofilm assays.
Prior to the bacteria infection, we confirmed that the BHI
medium used to suspend the phages and bacteria had no
significant effect on the larvae (Supplementary Figure S2). The
stability of the phages within the larvae was determined by
administering the phages via the oral cavity and analyzing phage
recovery from the feces and gut of the sacrificed insects using
spot test. Phages remained stable and recoverable from the insects
for up to 5 days (Supplementary Figure S3). To determine the
pattern of CD105LC2 colonization within the insects, a range
of doses were tested and we showed that 105 CFU caused the
death of all insects within 60 h, with first fatal case recorded
in the first 24 h post-infection (Supplementary Figure S2). As
expected, colonization progressed with time and approximately
108 CFU/larva of bacteria load was recovered at the end of the
treatment as opposed to ∼104 CFU/larva starting bacterial load
(Supplementary Figure S4).
To determine phage efficacy in this model, 3 regimens were
conducted on the insects. Survival and bacterial load were
ascertained and compared to untreated group (Figure 4A) and
to larvae inoculated with phages only (Figure 4B). Where the
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FIGURE 1 | Bacterial recovery from biofilms in pre- and post-biofilm treatments with combined and individual phages (CDHM1, 2, 5 and 6). (A) Set 1
represents the untreated biofilms while Sets 2–4 represent the pre-treatment regimens, where the phages were added after bacterial growth for 1 h (Set 2, B),
phages were incubated for 1 h before bacteria (Set 3, C) or mixed together before adding to plates (Set 4, D). (E) Represents viability counts after phage treatment
post-biofilm formation. Experiments were conducted with three replicates and repeated twice. Data was analyzed using GraphPad Prism 6. Error bars are SEM of all
replicates.
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FIGURE 2 | Scanning electron microscopy (SEM) analyses and bacterial enumeration from established C. difficile (CD105LC2) colony biofilms treated
with phage combination. (A) Topology of untreated biofilm. Impact of phage cocktail on topologies of Day 1 (B–D), Day 2 (E,F), Day 3 (G) and 4 (H) and Day 5
(untreated I and treated, J) biofilms are shown. Green arrows, plaques (lysed zones); orange arrows, unaffected areas; blue arrows, spore mother cells; yellow
arrows, spores; red arrow, elongated cells, and black arrows, disintegrated cells. Graphical representation of viability counts for spores and vegetative cells are
shown in (K).
insects were treated with phages 2 h before inoculating them
with the bacteria, the insects were completely protected with
100% survival rate within this group (Figures 4C and 5A).
This is comparable to the phage control group (Figure 4B).
When the larvae were given both the phages and the bacteria
simultaneously, efficacy was reduced to 98, 85, and 72% at the 36,
48, and 60 h respectively post inoculation (Figures 4D and 5A).
The least effective treatment was recorded in the remedial group
where phages were added 2 h post-bacteria. Infection resulted to
82, 65, and 30% survival at the three time points (Figures 4E and
5A). All larvae were dead at the end of the experiment, however,
(Figures 4F and 5A). The bacterial numbers at the end of the
experiments were consistent with results from the survival assays
(Figures 5B,C). The prophylactic group (Phages, CD105LC2)
had the lowest bacterial load with ∼102 CFU/larva recovered
while ∼106 CFU/larva were observed with the remedial group
and ∼104 CFU/larva when phages/bacteria were administered
simultaneously (Figure 5B). The treatments were statistically
significantly different (P < 0.0001). A similar trend was observed
with the qPCR data (Figure 5C). Sixty isolates were recovered
from all the treatment and testing them with the phage
combination showed that the isolates were still sensitive to the
phages.
Effect of Multiple Phage Doses on
C. difficile Colonization and Survival
in the Galleria Model
In an attempt to improve the efficacy of the phages administered
post-infection, we determined if the use of multiple phage
doses could improve the remedial treatment. This was indeed
the case and larvae given a single dose and 2 doses had
the lowest survival rates of ∼10 and 20% respectively, while
groups that received 3, 4, or 5 doses showed an increasing
improvement with survival rate of ∼60% at the end of the
experiment (Figure 6A). Treatments differences here were also
statistically significant (P < 0.0001). Again bacterial recovery
from the larva was consistent with decreased bacterial numbers
as the number of phage dosages increased. Approximately,
105 CFU/larva were recovered from the single dose group as
opposed to 102 CFU/larva from the group, which received five
doses (Figure 6B).
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FIGURE 3 | Confocal microscopy analyses of stained phage-treated colony biofilms. (A) T-section through a 24 h colony biofilm treated with phages and
stained with Live/Dead viability staining kit showed lysed zones (green arrow) and unaffected areas (orange arrow). (B) Shows mixture of live/dead cells in the biofilm.
(C) Shows normal bacterial morphology of the live cells. (D) Shows elongated dead cells in the biofilm. Biofilms were treated with Live/Dead Viability Kit, which
stained live cells green and the dead cells red by the Syto 9 and propidium iodide dyes respectively.
Phage Prophylactic Regimens and
Phage/Antibiotic Treatments
We showed that the phages remain viable within the Galleria
heamolymph for up to 5 days. In experiments shown in Figure 5,
phages were administered 2 h prior to bacterial infection. Here,
to determine the impact of giving phages to insects for longer
times before bacterial inoculation prophylactic periods of 2 h
(A), 6 h (B), 12 h (C), and 24 h (D) prior to bacterial infection
were examined. Interestingly, increased phage activity resulted
in increased phage counts in the 2–12 h delay times and
corresponding decreased bacterial counts as the time delay prior
to bacterial infection increased (∼102 CFU/larva at 24 h delay as
opposed to∼103 CFU/larva at 2 h delay) (Figure 7A).
When the phages were tested as adjuncts to vancomycin, but
given prior to bacterial challenge, vancomycin was less effective
at removing C. difficile (with ∼102 CFU/larva cells recovered)
(E) than if phages were not given. In contrast, when vancomycin
was given prophylactically before infection, the phages were
more effective, leading to only ∼10 CFU/larva recovered and
this therapy (F) is more effective than vancomycin treatment
(G), vancomycin/phage prophylaxis (H) and remedial treatment
(I) in which ∼102 CFU/larva were recovered in both regimens
(Figure 7A).
To mimic dysbiosis, clindamycin was given to the insects
before bacterial infection followed by phage treatment (J). Here,
we saw a proliferation of bacterial growth with ∼105 CFU/ml of
bacteria being recovered. However, if phages were given post-
clindamycin treatment and before bacterial infection (K), only
∼102 CFU/larva of bacteria were detected, which is comparable
to the combined phage/vancomycin prophylaxis (Figure 7A).
In terms of survival, larvae in groups A, B, C, D, E, F, H,
I, and K all survived but ∼10 and 30% of the larvae died
in the vancomycin treatment and clindamycin pre-treatment 1
(G and J) respectively (Figure 7B).
DISCUSSION
Clostridium difficile is a notorious nosocomial pathogen causing
fatalities in the immunocompromised. A limiting factor to the
control of the disease is the lack of treatment options (Zucca
et al., 2013; Hargreaves and Clokie, 2014). C. difficile produces
spores and biofilms that significantly contribute to its virulence
by enabling persistence and proliferation in the environment
and gut, and resistance to antimicrobial and cleaning agents
(Akerlund et al., 2008; Burns et al., 2011; Burns and Minton, 2011;
Dawson et al., 2012; Ðapa et al., 2013). Phages are antimicrobial
agents that can penetrate biofilms and could potentially be
developed to supplement the currently available CDI treatments
for better efficacy and clinical outcome (Cos et al., 2010; Morten
et al., 2011). Here, we examined the impact of an optimized
phage combination on C. difficile biofilms and tested their efficacy
both as a stand-alone treatment and as adjunct to vancomycin
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FIGURE 4 | Impact of phage treatment on the morphology and survival of G. mellonella larvae at the end of 60 h. Larvae were treated with either 105 CFU
of bacteria and/or 106 PFU of phages. The untreated (A), phage-only inoculated larvae (B) and prophylaxis group (C) remained healthy and yellow in color at the end
of the experiment. While some of the larvae in groups which received a mixture of phages and bacteria (D) and the remedial group (E) turned black in color. All larvae
in the control bacterial group (F) turned black in color at the end of the treatment. Larvae are considered dead when they turn black and remain motionless.
in a G. mellonella larva CDI model. We showed that the phages
can penetrate well-established C. difficile biofilms leading to
lysis, plaque formation and a reduction in bacterial viability and
biomass in vitro. A single phage treatment is effective in the
pre-biofilm treatment in vitro, and prophylactically in the insect
models, although multiple phage doses were needed to improve
the remedial regimen.
C. difficile Phages Could Target Biofilms
of a Prevalent Ribotype 014/020 Strain
To evaluate the potential efficacy of our phages for CDI
treatment, we targeted a clinically prevalent and severe ribotype
strain (CD105LC2, ribotype 014/020) (Indra et al., 2015; Lessa
et al., 2015). In addition to the pathogenicity of CD105LC2, our
previous data showed that the individual phages in the mix have
optimal plaquing efficiencies on the strain and this combination
could completely eradicate C. difficile in vitro and reduce its
colonization in a CDI hamster model (Nale et al., 2016). Having
previously established the efficacy of the phages on C. difficile
in vitro and on a hamster model, here we went further to test
their effect on the biofilm and insect models. This is to determine
if they are useful models in which to probe different aspects
of C. difficile-phage interaction which can inform their future
development, and of course useful models for the development
of other phages that target biofilm-producing bacteria.
Optimized Phage Combination Is More
Effective at Removing C. difficile Biofilms
Compared to Single Phage Treatments
When testing the efficacy of the phages on biofilms we showed
that the phage combination is more efficient at reducing biofilms
compared to using the single phages. This observation concurs
with previous findings, which showed that treatment of C. difficile
with single phage is commonly associated with the emergence
and proliferation of resistant or lysogenic clones (Ramesh et al.,
1999; Meader et al., 2010, 2013; Govind et al., 2011; Nale et al.,
2016). Like all previously characterized C. difficile phages, the
phages examined in this study have integrases in their genomes
and could potentially access the lysogenic pathway (Goh et al.,
2013; Hargreaves and Clokie, 2014). However, our previous data
using the optimized phage combination in vitro suggest that the
effect of resistance or lysogeny could be circumvented through
complementation (Nale et al., 2016). The data presented here
further supports this observation as the combined phages caused
clear patches of killing on the biofilms.
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FIGURE 5 | Impact of phage treatment on C. difficile colonization and
survival rates of G. mellonella larvae CDI model. (A) Survival curve
showing impact of phage treatment on the larvae in the prophylaxis group
(phages, CD105LC2), remedial (CD105LC2, Phages) regimens or larvae
treated with a mixture of phages and bacteria simultaneously
(phage + CD105LC2 (s)). The treatments were compared with control groups
where larvae were given phages only (Control phages) and those that received
bacteria only (CD105LC2 control). Bacterial enumeration on CCEY plates are
shown in (B), while (C) represents qPCR absolute quantification data targeting
C. difficile 16S rRNA and comparing with standard CD105LC2 curve.
A statistical significant difference in time to death was observed (p < 0.0001)
using four larvae per group and experiment was repeated three times. Error
bars are SEM of all the replicates. Data was analyzed using GraphPad
Prism 6.
C. difficile Phages Are Effective
Pre-biofilm Agents
We investigated three different pre-biofilm treatments with the
combined phage mixture. In all cases, a significant biofilm
reduction was observed. The clearance could be attributed to
the ability of the phages to either completely eliminate or
reduce the bacteria even before the biofilms were formed (Chan
and Abedon, 2015; Nale et al., 2016). When the phages were
incubated at 37◦C for an hour before the bacterial cultures
were added (Set 3), bacteria were eliminated beyond limit
of detection. Similar observation was made when catheters
were pre-treated with phages before exposure to Pseudomonas
aeruginosa biofilm (Fu et al., 2010). This could be attributed
to the phages being able to acclimatize to the incubation
temperature and conditioned to optimum bacteriolytc activity
before the bacterial culture was added (Taj et al., 2014).
Temperature plays key roles in the attachment, adsorption,
latent period, and multiplication of phages, and thus could
greatly affect their infectivity (Olson et al., 2004; Jon´czyk
FIGURE 6 | Impact of multiple phage doses on G. mellonella larvae CDI
model. Larvae were treated with a mixture of bacteria and phages at the
beginning of the experiment (one dose). Subsequently, the larvae received
single increment phage doses at 2, 6, 12, and 24 h, which represent 2, 3, 4,
and 5 doses respectively. Impact of phage treatment on larvae which received
all the dose regimens at the time points are presented. (A) Survival rates of
larva treated with the different doses. (B) Bacterial enumeration from the
larvae at the end of the experiment. Four larvae were examined in each group
and experiment was repeated three times. A statistical significant difference in
time to death was observed (p < 0.0001). Error bars represent SEM of all
replicates. Data was analyzed using GraphPad Prism 6.
et al., 2011). Efficacy was not as significant in Sets 2 and
4, where the phages were added directly from storage (at
4◦C) to the culture at 37◦C. Although the phages maintain
a stable latent period in storage, at lower than optimal
bacterial growth temperature, reduced attachment may take
place leading to decreased phage activity (Jon´czyk et al., 2011).
The temperature change encountered by the phages after being
transferred to 37◦C could have retarded their initial activity,
allowing the bacteria to multiply and thus led to reduced
MOI, and consequently recovery of bacteria in the phage-
treated culture. The reduced effect on the established biofilm
could potentially be attributed to less preference of phages
to mature biofilms (Abedon, 2016) or the negative impact
of PBS used for the biofilm washings on the activity of
the phages (Silva et al., 2014). Our preliminary data showed
that the stability of the phages in PBS is greatly reduced by
∼ 2 logs CFU/ml by 1 h (Supplementary Figure S5). This
observation is in agreement with a previous report (Silva et al.,
2014).
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FIGURE 7 | Analysis of phage prophylactic regimens and impact of combined phage/vancomycin treatment on the G. mellonella larvae. (A) Shows
phage and bacterial recovery after prophylactic treatment with phages and delays of 2, 6, 12, and 24 h in groups A, B, C and D respectively were observed before
bacterial exposure. Group E received phage followed by bacteria and vancomycin at the 2nd and 4th hour respectively. Group F was a reverse of group E. Group G,
is vancomycin remedial treatment. H group represents combined phage/vancomycin prophylaxis and I group is combined phage/vancomycin remedial regimen. J
and K regimen mimic dysbiosis where clindamycin was given first followed by bacteria then phage in J, but phages were given before bacteria in K. Larvae in
bacterial control group L received only bacteria. (B) Represents survival rates in the treatments. Four larvae were examined in each group. Experiment was repeated
three times. Error bars represent SEM of all replicates. Data was analyzed using GraphPad Prism 6.
Phages Could Impact Established
C. difficile Biofilms
Although we observed that the phages impacted the established
biofilms less than the pre-treated cultures, confocal and scanning
electron microscopy data both showed that the phages did
penetrate the – biofilms and clear phage plaques were formed
(Figure 2) (Abedon, 2016). In addition to the microscopy
observations, further evidence to suggest that the phages
penetrate the biofilm was indicated by the reduction in the
vegetative cell counts on up to day-4 biofilms. Sometimes, phage
lysis of biofilms is mediated by certain phage proteins which
could chemically degrade the extracellular polymeric substance
(EPS) found in the biofilm (Chan and Abedon, 2015). Previous
work conducted on C. difficile phages has shown that purified
endolysin is effective at clearing of the bacteria. Evidence to
suggest its activity on C. difficile biofilms is yet to be confirmed
(Mayer et al., 2008; Mayer and Narbad, 2012). Data from our
SEM analysis revealed that the clearance was restricted to healthy
vegetative cells only, thus we could attribute the clearance to lysis
from phage infection (Chan and Abedon, 2015; Abedon, 2016).
The observation of elongated dead cells in the lysed zones is
consistent with other findings that associated bacterial elongation
or plasticity with loss of normal cell division process, changes
in metabolic processes or DNA damage (Justice et al., 2008;
Ghaffar et al., 2015). This morphological change is associated
with stress conditions. Thus, conditions such as antimicrobial
treatments or starvation and have been reported in bacteria such
as Helicobacter pylori, Campylobacter and Listeria monocytogenes
(Takeuchi et al., 2006; van der Veen et al., 2010; Ghaffar et al.,
2015) and could trigger cell lysis (Kohanski et al., 2010). In
C. difficile, cell elongation was reported to be associated with
stress from treatment of the cells with sub-MIC of ridinilazole,
which caused the cells to increase from 4 µm to 100 µm in
length after 24 h treatment with the antibiotic (Bassères et al.,
2016). Although the mechanism of ridinilazole is not clear, this
response has been attributed to the SOS response and cell death
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from activity of β-lactam antibiotics (Kohanski et al., 2010).
This bacterial response to antimicrobial stress, leading to cell
elongation and death could possibly explain our observation of
filamentous cells at 24 h.
Phages Are Effective Prophylactic
Therapeutics and Adjuncts to
Vancomycin in G. mellonella CDI Model
We investigated the efficacy of the combined phages alone and
as adjuncts to vancomycin in G. mellonella larvae. Although
the insect is used as an infection model for various pathogens
(Mukherjee et al., 2010; Ramarao et al., 2012; Hill et al., 2014;
Beeton et al., 2015) and antimicrobial testing (Seed and Dennis,
2009; Abbasifar et al., 2014; Beeton et al., 2015; Olszak et al.,
2015), to our knowledge this report is the first published data
to describe its use to study C. difficile colonization and phage
treatment. We established that 105 C. difficile cells were sufficient
for colonization to occur in the larvae and to cause the first and
total mortality at 24 and 60 h respectively post-infection. The
choice of the inoculum dose and timing was optimal to allow
phage/vancomycin therapies to take place. Also, the bacterial
inocula we used were suspended in BHI broth. Previous reports
showed that bacteria were suspended either in PBS (Ramarao
et al., 2012; Hill et al., 2014) or in 0.9% NaCl (Mukherjee
et al., 2010, 2013). However, we could not use either of these
solutions since our phages are unstable in PBS, and the NaCl
solution negatively interfered with bacterial growth. Therefore,
the bacteria were re-suspended in cold BHI broth, which is
the growth medium for the bacteria and in which the phages
are stable. The BHI broth control is comparable to PBS and
NaCl as shown by the larval survival data (Supplementary
Figure S2).
We conducted our phage treatment at MOI of 10 to
allow comparison of the data from the current study with
our previous report (Nale et al., 2016). Work is ongoing to
examine other MOIs. Although previous work reported the
inoculation of bacteria/phages by intrahaemocoelic injection
(Abbasifar et al., 2014; Beeton et al., 2015), we found ingestion
via the oral route more efficient at inducing colonization and
producing reproducible therapy results. The observed higher
efficacy of the phages when used prophylactically rather than with
remedial treatment is consistent with a previous report (Beeton
et al., 2015). Interestingly, the best treatment was observed
when vancomycin was given prophylactically followed by phage
application. This is significant as it could potentially serve as
an intervention therapy to supplement vancomycin and prevent
disease relapse. Similarly, the effectiveness of increased window
time of having phages prior to bacterial infection could also be
attributed to the ability of the phages to be distributed throughout
the gut and acclimatize to the incubation temperature (Jon´czyk
et al., 2011; Beeton et al., 2015) for effective bacteriolysis. The
increased survival rates and corresponding decreased bacterial
counts observed with the multiple phage dose regimens could be
attributed to increased number of phages consequently leading to
increased MOI and activity.
CONCLUSION AND
RECOMMENDATIONS
The optimized phage combination studied here showed great
potential in the control of C. difficile biofilms. And the biofilm
model is useful for the development of phages that target both
this and other pathogenic bacteria. Pre-treating likely surfaces, or
potentially, cell lines is most effective as no colonization occurred
after their application. Again in the insect model, the phages
demonstrated a clear prophylactic potential as a stand-alone
treatment for CDI and as adjuncts to vancomycin in the remedial
treatment. These characteristics of the phages could be explored
further to prevent and control CDI.
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